These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 635389)

  • 1. [Secondary prevention of myocardial infarct. Evaluation of a 2-year trial comparing acetylsalicylic acid to oral anticoagulants].
    Rev Prat; 1978 Jan; 28(1):43-56. PubMed ID: 635389
    [No Abstract]   [Full Text] [Related]  

  • 2. [Platelet antiaggregants or anticoagulants in the secondary prevention after myocardial infarct].
    Di Pasquale G; Ottani F; Ceré E; Biancoli S; Sassone B; Lombardi A
    Recenti Prog Med; 1998 Oct; 89(10):514-9. PubMed ID: 9842255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on secondary prevention of myocardial infarct (EPSIM). Work of the EPSIM research group].
    Arch Mal Coeur Vaiss; 1982 Dec; 75 Spec No():1-130. PubMed ID: 6820624
    [No Abstract]   [Full Text] [Related]  

  • 4. [Anticoagulant or antiaggregant therapy in the secondary prevention of myocardial infarct?].
    De Caterina R; Gianetti J; Simonetti I; Gensini G
    G Ital Cardiol; 1996 Nov; 26(11):1309-21. PubMed ID: 9036028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E.P.S.I.M., the French oral anticoagulant--aspirin trial in post-myocardial infarction patients: design, organization and quality control procedures.
    Boissel JP; Leizorovicz A; Schbath J; Destors JM; Gillet J
    Scand J Haematol Suppl; 1981; 38():47-72. PubMed ID: 7038857
    [No Abstract]   [Full Text] [Related]  

  • 6. [New study on the secondary prevention of myocardial infarct using oral anticoagulants].
    de Jonge FA; Jonker JJ
    Ned Tijdschr Geneeskd; 1983 Jul; 127(31):1391-4. PubMed ID: 6621724
    [No Abstract]   [Full Text] [Related]  

  • 7. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group.
    Breddin K; Loew D; Lechner K; Oberla K; Walter E
    Circulation; 1980 Dec; 62(6 Pt 2):V63-72. PubMed ID: 6777073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Secondary prevention following a myocardial infarct].
    Enjalbert M; Théroux P; Bourassa MG
    Union Med Can; 1983 Mar; 112(3):219-20, 225-8, 234. PubMed ID: 6134369
    [No Abstract]   [Full Text] [Related]  

  • 9. [Anticoagulants or thrombocyte aggregation inhibitors in the prevention of recurrent heart infarction?].
    Volger E; Theiss W
    MMW Munch Med Wochenschr; 1983 Apr; 125(14):285-8. PubMed ID: 6406866
    [No Abstract]   [Full Text] [Related]  

  • 10. [Platelet anti-aggregant and anticoagulant therapy in the secondary prevention of coronary disease. Preliminary note].
    Caruzzo C; Belli R; Beasci R
    Boll Soc Ital Cardiol; 1977; 22(7):1027-35. PubMed ID: 618238
    [No Abstract]   [Full Text] [Related]  

  • 11. [Acetylsalicylic acid as antithrombotic agent in acute myocardial infarct without shock syndrome].
    Thiele G; Fiedler H
    Z Gesamte Inn Med; 1973 Feb; 28(3):36-8 passim. PubMed ID: 4701331
    [No Abstract]   [Full Text] [Related]  

  • 12. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
    Gianetti J; Gensini G; De Caterina R
    Thromb Haemost; 1998 Dec; 80(6):887-93. PubMed ID: 9869155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The antithrombotic treatment and prevention of recurrence with acetylsalicylic acid in myocardial infarct].
    Heuchel G; Hässler W
    Z Gesamte Inn Med; 1976 Feb; 31(3):61-5. PubMed ID: 1085534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study.
    Breddin K; Loew D; Lechner K; Uberla K; Walter E
    Thromb Haemost; 1979 Feb; 41(1):225-36. PubMed ID: 483232
    [No Abstract]   [Full Text] [Related]  

  • 16. [Long term prophylaxis of re-infarct. Results of the persantin-acetylsalicylic acid re-infarct study].
    Fortschr Med; 1980 Aug; 98(32):1227-8. PubMed ID: 7409723
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prevention of reinfarction with acetylsalicylic acid].
    Vogel G; Fischer C; Huyke R
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):797-803. PubMed ID: 94871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Secondary prevention after myocardial infarction--beta blockade and acetylsalicylic acid is the basic therapy].
    Bergstrand R; Johansson S; Ulvenstam G; Aberg A; Wilhelmsen L
    Lakartidningen; 1989 Jan; 86(1-2):47-50. PubMed ID: 2562999
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prolonged administration of anticoagulants after myocardial infarct].
    Asperger Z; Jursic M
    Lijec Vjesn; 1970 Mar; 92(3):369-74. PubMed ID: 4103258
    [No Abstract]   [Full Text] [Related]  

  • 20. [Summary: Secondary prophylaxis following myocardial re-infarct. Anticoagulants or thrombocyte function inhibitors?].
    Breddin K; Loeliger EA
    Internist (Berl); 1980 Jul; 21(7):399. PubMed ID: 7007281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.